Trial · NCT03357757
Avelumab With Valproic Acid in Virus-associated Cancer
NCT03357757, Phase 2, Completed, AHS Cancer Control Alberta
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Avelumab With Valproic Acid in Virus-associated Cancer. Trials, record NCT03357757. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03357757
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Avelumab With Valproic Acid in Virus-associated Cancer
- NCT number
- NCT03357757
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 39 participants, actual
- Lead sponsor
- AHS Cancer Control Alberta
- Conditions
Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona
- Interventions
- Valproic Acid, Avelumab
- First posted
- 2017-11-30
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of Avelumab and VPA | 1 year after enrolment of last patient | • Assessment of the clinical response rate according to the immune-related RECIST criteria (iRECIST) |
| Primary | Proportion of subjects who complete 4 doses of Avelumab in combination with VPA | 1 year after enrolment of last patient | • Feasibility analysis, defined as the proportion of subjects who complete 4 doses of Avelumab in combination with VPA over the total duration of the study. |
| Secondary | Overall survival | 5 years from final study drug dose | defined as the time from the date of enrollment to the date of death, whatever the cause. |
| Secondary | Progression free survival | 5 years from final study drug dose | Progression free survival is defined as the time between the date of treatment initiation and the date of disease progression or death (whatever the cause), whichever occurs first. |
| Secondary | Number of participants with adverse events | Through study completion, up to 2 years | • Incidence of adverse events (assessed as the incidence and severity of adverse events, including immune-related adverse events, and the number of discontinuations due to adverse events). |
| Secondary | Identify specific virus-associated cancers as candidates for subsequent study | Through study completion, up to 2 years | |
| Secondary | Measurement of Immuno-score | Through study completion, up to 2 years | AffymetriX Micro-array (Immuno-score) |
| Secondary | Measurement of MHC expression | Through study completion, up to 2 years | |
| Secondary | Measurement of cell-free tumoral DNA in blood | Through study completion, up to 2 years | |
| Secondary | Phenotyping of Tumour Infiltrating Lymphocytes | Through study completion, up to 2 years |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03357757
GET https://conductscience.org/api/trials/v1/NCT03357757/registered